Ovid Therapeutics (OVID) Other financing activities (2016 - 2022)

Ovid Therapeutics has reported Other financing activities for 7 years, with the latest figure at -$56943.0 in Q4 2022.

• For the quarter ending Q4 2022, Other financing activities changed N/A year-over-year to -$56943.0; the trailing twelve-month figure through Sep 2022 stood at $56943.0 (up 127.19% YoY), and the FY2021 full-year result was $21314.0, up 239.89% from the prior year.
• Other financing activities for Q4 2022 stood at -$56943.0, down from $56943.0 in the prior quarter.
• The five-year high for Other financing activities was $56943.0 in Q3 2022, with the low at -$56943.0 in Q4 2022.
• Historically, Other financing activities has averaged -$2883.7 across 5 years, with a median of -$395.0 in 2018.
• Annual changes were most pronounced in 2019 — Other financing activities sank 8636.0% — and 2020, when it jumped 117.17%.
• Ovid Therapeutics' Other financing activities stood at -$250.0 in 2018, then slumped by 8636.0% to -$21840.0 in 2019, then surged by 117.17% to $3750.0 in 2020, then soared by 468.37% to $21314.0 in 2021, then slumped by 367.16% to -$56943.0 in 2022.
• The last three Other financing activities figures came in at -$56943.0 (Q4 2022), $56943.0 (Q3 2022), and $4305.0 (Q2 2022), per Business Quant data.